MDM2 and cancer: By Western blot analysis, we showed that MDM2 was slightly decreased in both parental and USP22-Ko A549 cancer cells, while USP22 was significantly upregulated by P5091 treatment (Fig. 6D), which confirms that P5091 effectively inhibited USP7 deubiquitinase activity.